US6017748A - Cloning host organisms - Google Patents
Cloning host organisms Download PDFInfo
- Publication number
- US6017748A US6017748A US08/488,423 US48842395A US6017748A US 6017748 A US6017748 A US 6017748A US 48842395 A US48842395 A US 48842395A US 6017748 A US6017748 A US 6017748A
- Authority
- US
- United States
- Prior art keywords
- dna
- gene
- library
- culture
- coli
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000010367 cloning Methods 0.000 title abstract description 30
- 230000035772 mutation Effects 0.000 claims abstract description 72
- 230000037361 pathway Effects 0.000 claims abstract description 54
- 238000000034 method Methods 0.000 claims abstract description 23
- 230000033616 DNA repair Effects 0.000 claims abstract description 17
- 230000008707 rearrangement Effects 0.000 claims abstract description 17
- 108020004414 DNA Proteins 0.000 claims description 92
- 241000588724 Escherichia coli Species 0.000 claims description 44
- 210000004027 cell Anatomy 0.000 claims description 42
- 239000013612 plasmid Substances 0.000 claims description 27
- 238000005215 recombination Methods 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 230000006798 recombination Effects 0.000 claims description 24
- 108091027569 Z-DNA Proteins 0.000 claims description 17
- 238000010276 construction Methods 0.000 claims description 16
- 241000894006 Bacteria Species 0.000 claims description 15
- 101150021083 recB gene Proteins 0.000 claims description 14
- 101150056906 recJ gene Proteins 0.000 claims description 13
- 230000001580 bacterial effect Effects 0.000 claims description 11
- 230000002068 genetic effect Effects 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 10
- 101150115617 umuC gene Proteins 0.000 claims description 9
- 101150003576 uvrC gene Proteins 0.000 claims description 9
- 101100346446 Escherichia coli (strain K12) mrr gene Proteins 0.000 claims description 8
- 101150079876 mcrB gene Proteins 0.000 claims description 8
- 101150023497 mcrA gene Proteins 0.000 claims description 7
- 101150022503 phoR gene Proteins 0.000 claims description 7
- 101150079601 recA gene Proteins 0.000 claims description 7
- 108010042407 Endonucleases Proteins 0.000 claims description 5
- 102000004533 Endonucleases Human genes 0.000 claims description 5
- 101100467491 Methanopyrus kandleri (strain AV19 / DSM 6324 / JCM 9639 / NBRC 100938) rad50 gene Proteins 0.000 claims description 5
- 101150047315 sbcC gene Proteins 0.000 claims description 5
- 239000002299 complementary DNA Substances 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 2
- 210000000349 chromosome Anatomy 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 230000001131 transforming effect Effects 0.000 claims 2
- 230000008439 repair process Effects 0.000 abstract description 22
- 238000002744 homologous recombination Methods 0.000 abstract description 13
- 230000006801 homologous recombination Effects 0.000 abstract description 13
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 abstract description 4
- 230000004044 response Effects 0.000 abstract description 4
- 230000035939 shock Effects 0.000 abstract description 4
- 230000008649 adaptation response Effects 0.000 abstract description 2
- 230000029936 alkylation Effects 0.000 abstract description 2
- 238000005804 alkylation reaction Methods 0.000 abstract description 2
- 230000006378 damage Effects 0.000 abstract description 2
- 238000010348 incorporation Methods 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 230000033607 mismatch repair Effects 0.000 abstract description 2
- 230000003204 osmotic effect Effects 0.000 abstract description 2
- 229940035893 uracil Drugs 0.000 abstract description 2
- 230000026683 transduction Effects 0.000 description 17
- 238000010361 transduction Methods 0.000 description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 description 15
- 229960005091 chloramphenicol Drugs 0.000 description 14
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 14
- 238000012216 screening Methods 0.000 description 10
- 239000004098 Tetracycline Substances 0.000 description 9
- 229960002180 tetracycline Drugs 0.000 description 9
- 235000019364 tetracycline Nutrition 0.000 description 9
- 229930101283 tetracycline Natural products 0.000 description 9
- 150000003522 tetracyclines Chemical class 0.000 description 9
- 230000002950 deficient Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 101150109249 lacI gene Proteins 0.000 description 7
- CZVCGJBESNRLEQ-UHFFFAOYSA-N 7h-purine;pyrimidine Chemical group C1=CN=CN=C1.C1=NC=C2NC=NC2=N1 CZVCGJBESNRLEQ-UHFFFAOYSA-N 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000013011 mating Effects 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 5
- 230000000087 stabilizing effect Effects 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 238000007747 plating Methods 0.000 description 4
- 230000013120 recombinational repair Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 241001646716 Escherichia coli K-12 Species 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 101150085823 hsdR gene Proteins 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- -1 sbcC201 Proteins 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 230000002463 transducing effect Effects 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 101100355997 Bacillus subtilis (strain 168) recA gene Proteins 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 101100301301 Escherichia coli (strain K12) recE gene Proteins 0.000 description 2
- DGMPVYSXXIOGJY-UHFFFAOYSA-N Fusaric acid Chemical compound CCCCC1=CC=C(C(O)=O)N=C1 DGMPVYSXXIOGJY-UHFFFAOYSA-N 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 239000006137 Luria-Bertani broth Substances 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 101150059159 proA2 gene Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 101150011956 recD gene Proteins 0.000 description 2
- 101150002589 recF gene Proteins 0.000 description 2
- 101150033993 recR gene Proteins 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 101100402795 Caenorhabditis elegans mtl-1 gene Proteins 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101100301239 Myxococcus xanthus recA1 gene Proteins 0.000 description 1
- 229910021204 NaH2 PO4 Inorganic materials 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 101100223934 Yersinia pestis dkgA gene Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000006846 excision repair Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 101150070420 gyrA gene Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 101150070367 recC gene Proteins 0.000 description 1
- 101150037928 recN gene Proteins 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 101150098466 rpsL gene Proteins 0.000 description 1
- 101150072534 sbcB gene Proteins 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
Definitions
- This invention relates to certain methods and materials for the cloning of DNA and, in particular, to the cloning of "unclonable" DNA using a genetically engineered host cell.
- This cloning host organism includes particular mutations from existing cells which have been found to stabilize tester DNA plasmids, and can be assembled using standard transducing and plating techniques.
- the ability to elucidate gene structure and function often depends to a great extent upon the construction of recombinant DNA libraries accurately representing the total genome of a subject organism, followed by the cloning of this recombinant DNA.
- the total DNA of cells from the subject organism is isolated and cut into fragments using specific restriction enzymes.
- the fragmented DNA sequences are then inserted into appropriate vectors for subsequent propagation and amplification in a foreign host.
- Commonly used vectors include plasmids, cosmids or phages.
- host cells suitable for propagation of foreign DNA sequences include bacteria (i.e., E.
- Drosophilia i.e., Drosophilia melongaster mammalian cell lines (CHO, L-cells) human cell lines (i.e., Hela, Baculovirus, plant cell lines.
- DNA that is capable of forming cruciforms (hydrogen bonded hairpin structures formed from inverted repeat sequences) and Z-DNA (a left handed zig zag configured DNA resulting from alternating purine-pyrimidine residues), for example, is rapidly deleted or rearranged in E. coli.
- cruciforms hydrogen bonded hairpin structures formed from inverted repeat sequences
- Z-DNA a left handed zig zag configured DNA resulting from alternating purine-pyrimidine residues
- the present inventor has discovered that complex DNA sequences can be stabilized during cloning by utilizing hosts with combined mutations in certain nucleic acid recombination and repair pathways. Described herein are novel bacterial hosts designed for cloning foreign DNA by combining DNA repair mutations into host strains deficient in homologous recombination. Mutations which allow for stabilization of tester plasmids containing complex DNA are identified in existing strains and then assembled using standard techniques of transduction, screening, selection and propagation. The resulting bacteria can be used to stabilize and clone complex DNA such as contained in eucaryotic genomes.
- This invention provides for the genetic construction of host organisms that provide a stable environment for cloning foreign DNA molecules capable of assuming secondary and tertiary structure susceptible of rearrangement. These hosts are, thus, suitable for cloning DNA molecules capable of assuming such secondary and tertiary structures.
- the host organisms of this invention provide a stable environment for DNA molecules containing inverted repeat sequences, capable of forming cruciforms, and DNA molecules containing alternating purine-pyrimidine residues, capable of forming Z-DNA.
- the host organisms of the invention are characterized as being recombination deficient and containing genetic mutations in DNA repair pathways.
- this invention provides for an E.
- the invention further provides for a method of cloning structurally complex DNA, such as found in the eucaryotic genome.
- This method comprises isolating DNA from an organism, cutting the DNA into fragments, inserting DNA fragments of that organism into a vector, and introducing the vector in the insert into the host organism of this invention.
- the method involves the use of a host characterized as recombination deficient with mutations in DNA repair systems.
- the E isolating DNA from an organism, cutting the DNA into fragments, inserting DNA fragments of that organism into a vector, and introducing the vector in the insert into the host organism of this invention.
- the method involves the use of a host characterized as recombination deficient with mutations in DNA repair systems.
- the E isolating DNA from an organism, cutting the DNA into fragments, inserting DNA fragments of that organism into a vector, and introducing the vector in the insert into the host organism of this invention.
- the method involves the use of a host characterized as recombin
- coli host used in cloning is of the genotype recB, recJ, sbcC201, phoR, uvrC, umuC::Tn5, mcrA, mcrB, mrr, ⁇ (hsdRMS), endA1, gyrA96, thi, relA1, lac*, supE44, ⁇ F'proAB, lacI Q Z ⁇ M15::Tn10 ⁇ .
- This invention further provides for a method of constructing a host organism suitable for cloning DNA molecules capable of assuming secondary and tertiary structures susceptible of rearrangement.
- the method comprises identifying mutations of recombination and DNA repair pathways which stabilize DNA in existing hosts and assembling these mutations using standard genetic techniques.
- This invention further provides for construction of a novel strain of E. coli, designated SURETM Construction of the SURETM strain is accomplished by successively transducing E. coli ER1451 with bacterial genomes containing mutations in recombination and DNA repair systems.
- a preferred method of constructing the SURETM strain is outlined in FIG. 2 and further described herein.
- FIG. 2 is a flow diagram of the steps used to construct a strain of E. coli that is suitable for cloning DNA capable of forming secondary and tertiary structures susceptible of rearrangement.
- the SURETM strain was assembled from ER1451 using sequential steps of P1 transduction (P1) Bochner plating, and conjugal mating.
- P1 transduction P1 Bochner plating, and conjugal mating.
- the E. coli strain designation for each P1 transduction step indicates the source of genetic material transduced.
- the genotypes of these strains are set forth in Table 1.
- FIG. 1 is a schematic representation of the recombination pathways of E. coli.
- FIG. 3 is a schematic gene map of the inverted repeat tester plasmid, designated pAL28 ⁇ .
- FIG. 4 is a schematic gene map of the Z-DNA tester plasmid system, designated pAL20Z.
- lac*--an uncharacterized mutation within the lac operon which results in colonies more intensely blue in the presence of the lacZ ⁇ M15 mutation and a source of the ⁇ -complementation lac segment
- infection--any process used to introduce DNA into host organisms Includes transduction, transformation transtection, conjugal mating, and electroporation.
- restriction minus--cell strains lacking genes coding for enzymes which break down foreign DNA
- DNA molecules capable of assuming nonstandard secondary and tertiary structures, and as commonly found in eucaryotic genomes, are often completely deleted or rearranged during propagation in cloning host cells.
- a major reason for this lack of fidelity in cloning may be the existence in the host cell of mechanisms related to the replication and repair of DNA. Examples of such mechanisms include: (1) pathways designed for homologous or non-homologous recombination; (2) restriction systems which cleave foreign DNA sequences; (3) endonucleases which catalyze the breakdown of DNA; and (4) systems designed for repair of DNA.
- procaryotic and eucaryotic organisms have developed an extensive array of systems designed for DNA repair.
- repair systems include: uv repair pathway; SOS repair pathway; mismatch repair; adaptive response; heat shock response; osmotic shock response; repair of alkylation damage; repair of uracil incorporation into DNA; and gene products involved in maintaining DNA superhelicity.
- the role of such repair systems in cloning of foreign DNA has not yet been investigated. As noted above, prior attempts to increase stabilization of foreign DNA have focused only on host cell mutations in the recombination and/or restriction pathways.
- the inventors have engineered a host organism with mutations in repair as well as recombination pathways.
- the resulting host cells serve to stabilize various complex forms of DNA during propagation.
- the new strain has been designed to be a superior host for optimizing the construction of cDNA and genomic DNA libraries as well as for increasing the probability that the individual clones obtained will accurately reflect the genetic makeup of the subject organism.
- the construction of host strains with combined mutations was accomplished by crossing or mating strains with individual mutations in metabolic pathways.
- Means of constructing new strains by DNA introduction or mutation include, but are not limited to, Hfr mating, generalized transduction, specialized transduction, conjugation, transposon mutagenesis, oligonucleotide-directed mutagenesis, and transformation followed by genetic recombination.
- transducing bacteriophages include, but are not limited to, P1 or lambda.
- Example 1 Details of a preferred method of construction using P1 phage transduction are presented in Example 1. Screening and identification of mutant strains incorporating and expressing the transduced foreign DNA can be accomplished by any number of methods. Examples of such identification and screening methods include, but are not limited to, screening for phenotypic traits such as antibiotic sensitivity, drug resistance, or dependency on nutrient sources.
- the parent strain used as the basis for construction, can be any existing strain with a well-defined genotype that preferably includes at least one of the specific mutations sought to be present in the final genotype. Numerous such strains are available and have been well characterized. See, e.g., Ishiura, M., Hazumi, N., Koide, T., Uchida, T., and Okada, Y. (1989) J. Bact. 171:1068-1074.
- the parent strain is then transduced with or mated with DNA from a second strain known to contain at least one additional desired mutation. Those progeny cells containing the desired mutations from both the donor and recipient cell are identified, propagated and used through subsequent transduction or mating steps.
- the invention is a propagatable cell containing combined mutations in both recombination and DNA repair systems.
- the cloning host cell also contains mutations in the endonuclease and restriction systems, which mutations increase the utility of host cells for cloning purposes.
- the inventors have engineered and constructed a novel strain of E. coli, with combined mutations in recombination and repair systems, that stabilizes complex foreign DNA during propagation.
- E. coli strain ER1451 known to have mutations of certain DNA endonucleases and components of the restriction pathway, was sequentially transduced with bacterial genomes having the mutations sought to be introduced. In each case, the transduced DNA also contained a gene for tetracycline resistance. Following each individual transduction step, strains containing the combined mutations were screened on Bochner plates in order to isolate tetracycline sensitive derivatives which would then serve as a recipient for the next transduction step. Successive transduction steps can be performed in any order.
- the ER1451 strain was transduced sequentially with DNA containing mutations in the recombination pathway, ultraviolet repair pathway, SOS repair pathway, the restriction pathway, a tetracycline-resistant F'episome carrying a blue/white screening cassette and a lactose sensitivity gene.
- a strain of bacteria was created that is recombination deficient, restriction minus, endonuclease deficient, and with mutations in DNA repair systems. Details of this preferred construction sequence are given in Example 1.
- the resulting bacterial host, constructed by this method, is known as SURE, a trademark of Stratagene Cloning Systems.
- the SURETM strain constructed by this method was then tested to determine its effect on the stability of cloned DNA sequences capable of forming secondary and tertiary structures and susceptible to rearrangement during propagation.
- DNA sequences include, but are not limited to inverted repeats and alternating purine-pyrimidine residues.
- inverted repeat plasmid tester system was created by modifying plasmid pBR322. This tester plasmid system, designated pAL28 ⁇ , used chloramphenicol resistance as the inverted repeat sequence.
- pAL28 ⁇ This tester plasmid system, designated pAL28 ⁇ , used chloramphenicol resistance as the inverted repeat sequence.
- a variety of strains of E. coli, existing strains as well as the SURETM strain were infected with a tester inverted repeat plasmid. Inverted repeats were found to be rapidly rearranged in virtually all existing strains tested. In contrast to the results with existing strains, however, the SURETM strain was found to provide a stabilizing environment for these inverted repeat sequences.
- the percentage of rearrangement was decreased 20 fold in the SURETM strain when compared to the other strains tested.
- the SURETM strain was, therefore, engineered to carry mutations blocking pathways responsible for repairing DNA lesions.
- Preferred specific mutations for blocking these two key pathways are uvrC and umuC respectively, although mutations in other genes of this pathway or mutations in other repair pathways would give the desired effect. This presence of these mutations was demonstrated to result in a 10 to 20 fold increase in stability of DNA containing long inverted repeats.
- Z-DNA tester plasmids were created as derivatives of plasmid pBR322.
- the pBR322 plasmid containing sequences for tetracycline and penicillin resistance, was modified to include a Z-DNA segment in the promoter region for chloramphenicol resistance.
- the newly created tester plasmid system was designated pAL20Z.
- This tester DNA plasmid was infected into existing strains of E. coli as well as the newly constructed SURETM strain.
- the Z-DNA containing segments were quickly deleted in the existing strains while, in the SURETM strain, deletion was significantly and markedly reduced.
- homologous recombination is a complex, multicomponent process that can proceed by three interdependent pathways (see FIG. 1). These 3 pathways, recBCD, recE and recF, all require the recA gene product and a set of accessory proteins.
- a standard recA host therefore, is completely deficient in homologous recombination.
- Recombination in a recb strain (the recBCD pathway is the primary pathway in a wild type E. coli) is reduced to approximately 0.5%.
- the residual activity is due to the presence of the recE and recF alternate pathways which do not involve recB.
- a recB recJ double mutant is virtually identical to a recA strain in its recombination deficiency; recJ is required for both alternate pathways.
- recombination can be blocked in host organisms with a variety of mutations. In addition to the ones set forth above, examples of such alternate mutations include recB, reco and recB, recJ, recN.
- the inventors discovered that insertion of either the recA or recB mutations into a sbcC, recJ, umuC, uvrC strain, stabilized both Z-DNA and inverted repeats.
- the recB derivative was found to exhibit superior stabilization effects. This discovery, that combined mutations in recombination and DNA repair pathways, stabilize complex DNA during propagation is significant.
- the cloning host organism of the instant invention is restriction minus, preferably carrying, in E. coli, hsd, mcr and mrr mutations.
- the absence of mcr and mrr restriction activity increases the size and representation of libraries constructed with methylated or hemimethylated DNA.
- the absence of hsd activity increases the size and representation of libraries constructed from sequences containing EcoK recognition sequences.
- An end mutation inactivating a DNA endonuclease was observed to result in mproved quality of plasmid DNA minipreps.
- the host cell of this invention also harbors a tetracycline-resistant F'episome carrying the lacI Q Z ⁇ M15 cassette making it suitable for blue/white screening on plates supplemented with X-gal and IPTG.
- the uncharacterized mutation present in XL1-Blue cells which makes both plaques and colonies more intensely blue when a source of the ⁇ -complementation fragment is introduced, has been added.
- the cell is, thus, suitable for plasmid or phage libraries using a variety of vectors.
- a novel strain of E. coli was constructed from existing strains utilizing standard transduction and plating techniques. In this example, transduction with P1 phage particles was utilized. Bochner plating was then used to screen derivatives for the desired genotype.
- An outline of the construction method is schematically diagramed in FIG. 2. The genotypes of the various E. coli strains used in the construction pathway are set forth in Table 1.
- ER1451 cells were grown at 37° C. to a density of 5 ⁇ 10 8 to 1 ⁇ 10 9 cells/ml in media containing tryptone, yeast extract, NaCl and agar (LB media) containing 5 mM CaCl 2 .
- Cells were harvested by centrifugation and resuspended in 100 mM MgSo 4 , 5 mM CaCl 2 (MC media) media at 37° C. for 15 minutes. Cells were again harvested by centrifugation and resuspended in 1/10 the original volume of MC media.
- 0.1 ml of the resulting cell suspension was mixed with a P1 phage, containing the genome of E. coli strain CES229, and incubated at 37° C. for 15 minutes.
- the reaction was terminated by the addition of 0.1 ml of 0.2M sodium citrate. 0.5 ml of LB media was added and cultures grown at 37° C. for an additional 60 minutes. These incubation conditions were found to be sufficient for expression of transduced DNA. Cells (5 ⁇ 10 6 ) were then plated directly onto LB plates containing 15 ⁇ g/ml tetracycline. Transductants were screened for the desired phenotype, then plated onto Bochner plates and screened for tetracycline sensitivity.
- the culture media for this screening procedure contained in final concentration: 10 g/L tryptone, 5 g/L yeast extract, 15 g/L agar, 10 g/L NaCl, 10 g/L NaH 2 PO 4 , 2 g/L glucose, 12 mg/L fusaric acid, 0.1 mM ZnCl 2 , and 50 mg/L of chlortetracycline.
- Cell colonies demonstrating a rapid rate of growth and sensitivity to tetracycline were identified, recovered and utilized for subsequent transduction as indicated in FIG. 2.
- ER1451 cells were sequentially transduced with P1 phages containing the genome of E.
- SURETM a trademark of Stratagene Cloning Systems.
- the genotype of SURETM is recB, recJ, sbcC201, phoR, uvrC, umuC::Tn5, mcrA, mcrB, mrr, ⁇ (hsdRMS), endA1, gyrA96, thi, relA1, lac*, supE44, ⁇ F'proAB, lacI Q Z ⁇ M15, Tn10 ⁇ .
- SURETM strain of E. coli was then used to test for stability of various structurally complex DNA sequences.
- DNA molecules containing an inverted repeat sequence coding for chloramphenicol resistance were created and inserted into modified pBR322 plasmid vectors.
- a gene map of the inverted repeat tester system, designated plasmid pAL28 ⁇ , is schematically diagramed in FIG. 3. Numerous strains of E. coli, including the SURETM strain, were transformed with pAL28 ⁇ . Transformants were inoculated in media containing only penicillin and grown for up to 100 generations (with serial dilutions). After every 10 or 20 generations, aliquots of cells were screened on either penicillin containing or chloramphenicol containing plates. Cells in which the inverted repeat chloramphenicol resistant sequences were rearranged lost their chloramphenicol resistance.
- DNA molecules were created which contained alternating purine and pyrimidine residues capable of forming Z-DNA. These Z-DNA containing sequences were inserted into a modified pBR322 plasmid designated pAL20Z (see FIG. 4). A sequence of 26 alternating purine-pyrimidine residues (GC) were inserted into and blocked expression of the promoter region for chloramphenicol resistance. Because of the absence of a promoter in the intact plasmid, host cells containing pAL20Z demonstrate chloramphenicol sensitivity. Deletion of the repeating sequences results in reconstitution of the promoter and, therefore, expression of chloramphenicol resistance. A variety of E. coli host strains were transformed with pAL20Z.
- GC purine-pyrimidine residues
- Transformants were inoculated into media containing penicillin and grown for up to 200 generations (with serial dilutions). After every 20 generations, 10 6 cells were plated onto media containing chloramphenicol (50 ⁇ g/ml). The percentage of cells demonstrating chloramphenicol resistance was taken as a direct reflection of the percent of cells rearranging the tester plasmid.
- the results from transformation of seven of these E. coli strains, including the SURETM strain, are shown below in Table 3. The genotypes of these E. coli strains can be found in Table 1.
- the SURETM E. coli strain significantly and markedly reduced the amount of DNA rearrangement.
- the SURETM strain therefore, provides a stabilizing environment for Z-DNA.
- the data from Examples 2 and 3 demonstrate that a cloning host organism can be engineered and constructed such that it provides a stabilizing environment for complex DNA molecules capable of forming secondary and tertiary structures.
- this host organism is effective in inhibiting rearrangements of DNA molecules capable of forming a variety of such secondary and tertiary structures.
- a novel strain of bacteria has been engineered by combining a number of mutations which significantly reduce the rate of both homologous and non-homologous recombination within segments of cloned foreign DNA.
- Non-bacterial DNA particularly from eucaryotic sources, frequently contain sequences capable of forming secondary and tertiary structures such as cruciforms (due to presence of inverted repeats) or Z-DNA (found in alternating purine-pyrimidine stretches). These structures are highly recombinogenic in standard bacterial cloning hosts which are incapable of carrying out homologous recombination. Mutations which eliminate certain repair pathways responsible for excision of or replication past DNA lesions greatly stabilize these unusual structures. By engineering mutations which eliminate these pathways into a host strain deficient in homologous recombination, a novel host that is suitable for cloning foreign DNA has been constructed.
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
TABLE # 1 ______________________________________ Genotypes Strain ______________________________________ ER1451 Δ(lac-proAB), thi, gyrA96, endA1, hsdR17, relA1, supE44, {F' traD36, proAB, lacI.sup.Q Z M15} CES229 recD1009, hsdR, sbcC201, phoR79::Tn10, recA JC12166 recB21, recC22, sbcB15, sbcC201, thr-1, leuB6, thi-1, lacY1, galk2, ara-14, xyl-5, mtl-1, proA2, his-4, argE3, rpsL31, tsx-33, sup44, recJ284::Tn10 CAG12156 MG1655 (E. coli K-12 F.sup.- ) uvrC279::Tn10 JC8947 AB1157 (standard E. coli K-12) umcC::Tn5 AG279 same as JC12166 except recJ.sup.+, recF143, fuc::Tn10 JH122 GW1000 (standard E. coli K12, mcrB4::Tn10, mrr2::Tn5, hsdR2) BB4 hsdR514, supE44, supP58, lacY1, galK2, galT22, metB1, trpR55, {F'(lacI.sup.Q Z M15::Tn10} AG239 thi, gyrA, supE44, lac.sup.- (uncharacterized) Tet.sup.R AG1 recA, endA1, gyrA96, thi, hsdR17, supE44, relA C600· supE44, thi-1, leuB6, lacY1, tonA21, mcrA NM621· recD, hsdR, mcrA, mcrB, supE HB101 hsdS20, supE44, ara14, galK2, lacY1, proA2, rpsL20, xyl-5, recA13, mcrB TBI· ara, (lac-proAB), rpsL, 80, lacZ M15, hsdR DH5α recA1, endA1, relA1, thi, hsdR17, supE44, gyrA96 ______________________________________
TABLE # 2 ______________________________________ STABILITY OF INVERTED REPEATS IN VARIOUS E. COLI STRAINS Percentage of cells generating rearranged Strain plasmid per generation.sup.a ______________________________________ AG1 15-20 DH5α 15-20 C600 20-25 NM621 20-25 HB101 15-20 TB1 20-25 DL538 20-25 SURE ™ 0.8-1.2 ______________________________________ .sup.a Percent rearrangement calculated from the number of cells maintaining the inverted repeat tester plasmid in its unrearranged configuration (chloramphenicol resistant) divided by the total number of plasmidcontaining cells.
TABLE # 3 ______________________________________ STABILITY OF Z-DNA IN VARIOUS E. COLI STRAINS Percentage of cells generating rearranged Strain plasmids per 25 generations.sup.a ______________________________________AG1 15DH5α 15 C600· 10 NM621· 20HB101 15 TB1· 10 SURE ™ strain <0.1 ______________________________________ .sup.a Percent ZDNA rearrangement calculated by determining the percentag of chloramphenicol resistant cells (indicative of a specific ZDNA rearrangement) within a population after 25 generations.
Claims (24)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/488,423 US6017748A (en) | 1990-01-08 | 1995-06-07 | Cloning host organisms |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46250590A | 1990-01-08 | 1990-01-08 | |
| US5157293A | 1993-04-22 | 1993-04-22 | |
| US08/441,368 US5552314A (en) | 1990-01-08 | 1995-05-15 | Cloning host organisms |
| US08/488,423 US6017748A (en) | 1990-01-08 | 1995-06-07 | Cloning host organisms |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US08/441,368 Continuation US5552314A (en) | 1990-01-08 | 1995-05-15 | Cloning host organisms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US6017748A true US6017748A (en) | 2000-01-25 |
Family
ID=23836676
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US08/441,368 Expired - Lifetime US5552314A (en) | 1990-01-08 | 1995-05-15 | Cloning host organisms |
| US08/488,423 Expired - Lifetime US6017748A (en) | 1990-01-08 | 1995-06-07 | Cloning host organisms |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US08/441,368 Expired - Lifetime US5552314A (en) | 1990-01-08 | 1995-05-15 | Cloning host organisms |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US5552314A (en) |
| EP (2) | EP0437071A1 (en) |
| JP (1) | JPH04211361A (en) |
| AT (1) | ATE201047T1 (en) |
| CA (1) | CA2033355C (en) |
| DE (1) | DE69033732T2 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030123883A1 (en) * | 1998-11-04 | 2003-07-03 | The Research Foundation Of State University Of New York | Method and apparatus for detecting radiation |
| WO2005121351A2 (en) | 2004-05-27 | 2005-12-22 | Novozymes, Inc. | Methods for transforming and expression screening of filamentous fungal cells with a dna library |
| US20090203125A1 (en) * | 2006-05-02 | 2009-08-13 | Washington State University | Mig-7 as a specific anticancer target |
| WO2018094181A1 (en) | 2016-11-21 | 2018-05-24 | Novozymes A/S | Yeast cell extract assisted construction of dna molecules |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69033732T2 (en) * | 1990-01-08 | 2001-10-11 | Stratagene, La Jolla | New host organisms for cloning |
| US6143557A (en) * | 1995-06-07 | 2000-11-07 | Life Technologies, Inc. | Recombination cloning using engineered recombination sites |
| US6720140B1 (en) * | 1995-06-07 | 2004-04-13 | Invitrogen Corporation | Recombinational cloning using engineered recombination sites |
| CN101125873A (en) * | 1997-10-24 | 2008-02-20 | 茵维特罗根公司 | Recombinational cloning using nucleic acids having recombination sites |
| DE69836092T2 (en) | 1997-10-24 | 2007-05-10 | Invitrogen Corp., Carlsbad | RECOMBINATORY CLONING USING NUCLEAR FACILITIES WITH RECOMBINATION CENTERS |
| EP1100890A2 (en) | 1998-07-27 | 2001-05-23 | Genentech, Inc. | Improved transformation efficiency in phage display through modification of a coat protein |
| AU3387500A (en) * | 1999-03-02 | 2000-09-21 | Invitrogen Corporation | Cells resistant to toxic genes and uses thereof |
| DE60042969D1 (en) | 1999-03-02 | 2009-10-29 | Life Technologies Corp | PREPARATIONS AND METHODS FOR USE IN RECOMBINATORY CLONING OF NUCLEIC ACIDS |
| EP1250453B1 (en) | 1999-12-10 | 2008-04-09 | Invitrogen Corporation | Use of multiple recombination sites with unique specificity in recombinational cloning |
| US7198924B2 (en) | 2000-12-11 | 2007-04-03 | Invitrogen Corporation | Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites |
| EP2287341B1 (en) | 2003-12-01 | 2013-02-13 | Life Technologies Corporation | Nucleic acid molecules containing recombination sites and methods of using the same |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5512468A (en) * | 1993-11-12 | 1996-04-30 | Stratagene | Process of producing highly transformable bacterial cells and cells produced thereby |
| US5552314A (en) * | 1990-01-08 | 1996-09-03 | Stratagene | Cloning host organisms |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4190495A (en) * | 1976-09-27 | 1980-02-26 | Research Corporation | Modified microorganisms and method of preparing and using same |
| US4748119A (en) * | 1983-09-19 | 1988-05-31 | Alexander Rich | Process for altering and regulating gene expression |
-
1990
- 1990-12-19 DE DE69033732T patent/DE69033732T2/en not_active Expired - Lifetime
- 1990-12-19 AT AT95109717T patent/ATE201047T1/en not_active IP Right Cessation
- 1990-12-19 EP EP90313918A patent/EP0437071A1/en not_active Ceased
- 1990-12-19 EP EP95109717A patent/EP0681025B1/en not_active Expired - Lifetime
- 1990-12-28 CA CA002033355A patent/CA2033355C/en not_active Expired - Fee Related
-
1991
- 1991-01-07 JP JP3011461A patent/JPH04211361A/en active Pending
-
1995
- 1995-05-15 US US08/441,368 patent/US5552314A/en not_active Expired - Lifetime
- 1995-06-07 US US08/488,423 patent/US6017748A/en not_active Expired - Lifetime
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552314A (en) * | 1990-01-08 | 1996-09-03 | Stratagene | Cloning host organisms |
| US5512468A (en) * | 1993-11-12 | 1996-04-30 | Stratagene | Process of producing highly transformable bacterial cells and cells produced thereby |
Non-Patent Citations (15)
| Title |
|---|
| Bachmann 1983 Microbiol. Rev. 47(2): 180 230. * |
| Bachmann 1983 Microbiol. Rev. 47(2): 180-230. |
| Bullock et al. 1987 Bio Techniques 5(4): 376 379. * |
| Bullock et al. 1987 Bio Techniques 5(4): 376-379. |
| Chalker et al. 1988 Gene 71: 201 205. * |
| Chalker et al. 1988 Gene 71: 201-205. |
| Heitman et al. 1987 J. Bacteriol. 169(7): 3243 3250. * |
| Heitman et al. 1987 J. Bacteriol. 169(7): 3243-3250. |
| Ishiura et al. 1989 J. Bacteriol. 171(2): 1068 1074. * |
| Ishiura et al. 1989 J. Bacteriol. 171(2): 1068-1074. |
| Kolodner et al. 1985 J. Bacteriol. 163(3): 1060 1066. * |
| Kolodner et al. 1985 J. Bacteriol. 163(3): 1060-1066. |
| Raleigh et al. 1986 Proc. Natl. Acad. Sci., USA 83: 9070 9074. * |
| Raleigh et al. 1986 Proc. Natl. Acad. Sci., USA 83: 9070-9074. |
| Watson et al. 1987 in: Molecular Biology Of The Gene, fourth edition, Benjamin/Cummings Publishing Company, Menlo Park, CA, p. 313. * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030123883A1 (en) * | 1998-11-04 | 2003-07-03 | The Research Foundation Of State University Of New York | Method and apparatus for detecting radiation |
| WO2005121351A2 (en) | 2004-05-27 | 2005-12-22 | Novozymes, Inc. | Methods for transforming and expression screening of filamentous fungal cells with a dna library |
| US20090203125A1 (en) * | 2006-05-02 | 2009-08-13 | Washington State University | Mig-7 as a specific anticancer target |
| US9090699B2 (en) | 2006-05-02 | 2015-07-28 | J. Suzanne Lindsey | Mig-7 as a specific anticancer target |
| WO2018094181A1 (en) | 2016-11-21 | 2018-05-24 | Novozymes A/S | Yeast cell extract assisted construction of dna molecules |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0681025A1 (en) | 1995-11-08 |
| EP0681025B1 (en) | 2001-05-09 |
| EP0437071A1 (en) | 1991-07-17 |
| CA2033355C (en) | 2001-07-24 |
| CA2033355A1 (en) | 1991-07-09 |
| US5552314A (en) | 1996-09-03 |
| ATE201047T1 (en) | 2001-05-15 |
| DE69033732T2 (en) | 2001-10-11 |
| JPH04211361A (en) | 1992-08-03 |
| DE69033732D1 (en) | 2001-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6017748A (en) | Cloning host organisms | |
| Murphy et al. | PCR-mediated gene replacement in Escherichia coli | |
| US8043842B2 (en) | Bacteria with reduced genome | |
| US6365410B1 (en) | Directed evolution of microorganisms | |
| Kogoma et al. | The DNA replication priming protein, PriA, is required for homologous recombination and double-strand break repair | |
| Chalker et al. | Escherichia coli sbcC mutants permit stable propagation of DNA replicons containing a long palindrome | |
| Roth et al. | Rearrangements of the bacterial chromosome: formation and applications | |
| US7858358B2 (en) | Rapid growing microorganisms for biotechnology applications | |
| Slauch et al. | [5] IVET and RIVET: use of gene fusions to identify bacterial virulence factors specifically induced in host tissues | |
| Fehér et al. | Systematic genome reductions: theoretical and experimental approaches | |
| US20120100616A1 (en) | Method of double crossover homologous recombination in clostridia | |
| US20050032225A1 (en) | Competent bacteria | |
| Dri et al. | Role of the histone-like proteins OsmZ and HU m homologous recombination | |
| Kulakauskas et al. | Efficient introduction of cloned mutant alleles into the Escherichia coli chromosome | |
| US8765408B2 (en) | Prophage element-free bacteria | |
| CN111850025B (en) | A kind of gene editing system and method applied to Mycobacterium tuberculosis | |
| US20060270043A1 (en) | Bacteria with reduced genome | |
| Harvey et al. | Exchange of spacer regions between rRNA operons in Escherichia coli. | |
| EP2634256A1 (en) | De novo integron recombination sites and uses thereof | |
| US6706525B1 (en) | Highly transformable bacterial cells and methods for producing the same | |
| Sung et al. | Escherichia coli Genome Engineering and Minimization forthe Construction of a Bioengine | |
| Lloyd | Linkage distortion following conjugational transfer of sbcC+ to recBC sbcBC strains of Escherichia coli | |
| Grogan | Genetic properties of Sulfolobus acidocaldarius and related Archaea | |
| Galitski | Evolutionary approaches to the mechanisms of homologous recombination and mutability | |
| AU5623200A (en) | Rapid growing microorganisms for biotechnology applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: UNION BANK, CALIFORNIA Free format text: SECURITY INTEREST;ASSIGNOR:STRATAGENE;REEL/FRAME:007837/0408 Effective date: 19951201 |
|
| AS | Assignment |
Owner name: UNION BANK OF CALIFORNIA, N.A., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UNION BANK;REEL/FRAME:007991/0247 Effective date: 19960401 |
|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
| FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| AS | Assignment |
Owner name: MERRILL LYNCH BUSINESS FINANCIAL SERVICES INC., IL Free format text: SECURITY INTEREST;ASSIGNOR:STRATAGENE CORPORATION;REEL/FRAME:014926/0078 Effective date: 20040121 Owner name: STRATAGENE CALIFORNIA, CALIFORNIA Free format text: CHANGE OF NAME;ASSIGNOR:STRATAGENE;REEL/FRAME:016182/0616 Effective date: 20031209 |
|
| AS | Assignment |
Owner name: STRATAGENE, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UNION BANK OF CALIFORNIA, N.A.;REEL/FRAME:014885/0317 Effective date: 20040115 |
|
| AS | Assignment |
Owner name: MERILL LYNCH BUSINESS FINANCIAL SERVICES INC., ILL Free format text: SECURITY AGREEMENT;ASSIGNOR:STRATAGENE CALIFORNIA;REEL/FRAME:015167/0632 Effective date: 20040121 |
|
| AS | Assignment |
Owner name: TCW SPECIAL CREDITS FUND V-THE PRINCIPAL FUND C/O Free format text: SECURITY AGREEMENT;ASSIGNOR:STRATAGENE CALIFORNIA, FORMERLY KNOWN AS STRATAGENE;REEL/FRAME:014981/0654 Effective date: 20040203 |
|
| AS | Assignment |
Owner name: TCW SPECIAL CREDITS FUND V - THE, CALIFORNIA Free format text: SECURITY AGREEMENT;ASSIGNOR:STRATAGENE CALIFORNIA, FORMERLY KNOWN AS STRATAGENE;REEL/FRAME:014981/0660 Effective date: 20040203 |
|
| FPAY | Fee payment |
Year of fee payment: 8 |
|
| AS | Assignment |
Owner name: STRATEGENE CALIFORNIA, CALIFORNIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:MERRILL LYNCH BUSINESS FINANCIAL SERVICES, INC.;REEL/FRAME:021952/0174 Effective date: 20081030 |
|
| AS | Assignment |
Owner name: AGILENT TECHNOLOGIES, INC., COLORADO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:STRATAGENE CALIFORNIA;REEL/FRAME:024630/0870 Effective date: 20100615 |
|
| FPAY | Fee payment |
Year of fee payment: 12 |